RE:RE:RE:RE:RE:RE:RE:RE:Promises vs Expectations So there's two possibilities from 2017. Either they were outright lying or they failed to understand the challenges in this business model. I tend to think the latter. In 2023 they are at least talking around those challenges although with not a great deal of transparency.
There must be a big cliff somewhere near Reliq. If it's true there are 500,000 onboarded patients and revenue suggests there is only 10,000 or so revenue generating patients then that's the big cliff. That's where all reliq promises/projections/intentions go to die if you can't convert onboarded patients into revenue generating patients. That's both 2017 promises and if they don't solve the problems now then 2023 promises as well. The best I've got is at least they are acknowledging those problems in 2023. I don't know they have yet found a scalable solution to that problem.
Mitch43 wrote: Excellent, it allows us to realise when comparing 2017 to the present situation that Reliq hasn't grown SP by much when you factor inflation.
2017 share price had already attained 0.79 with less than 10k patients....
As a sharehoder investor... I'm not much interested by what the CO does... I'm more fixated on the SP and volumes variations.